Market open
Gyre Therapeutics/$GYRE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Gyre Therapeutics
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Ticker
$GYRE
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
579
Website
GYRE Metrics
BasicAdvanced
$637M
141.44
$0.05
-
-
Price and volume
Market cap
$637M
52-week high
$19.00
52-week low
$6.17
Average daily volume
196K
Financial strength
Current ratio
3.32
Quick ratio
2.636
Long term debt to equity
0.899
Total debt to equity
1.624
Management effectiveness
Return on assets (TTM)
8.38%
Return on equity (TTM)
20.24%
Valuation
Price to earnings (TTM)
141.44
Price to revenue (TTM)
5.471
Price to book
9.27
Price to tangible book (TTM)
9.53
Price to free cash flow (TTM)
-85.485
Growth
Revenue change (TTM)
-6.78%
Earnings per share change (TTM)
-103.41%
GYRE News
AllArticlesVideos
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
GlobeNewsWire·4 days ago
Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology
GlobeNewsWire·1 week ago
Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Gyre Therapeutics stock?
Gyre Therapeutics (GYRE) has a market cap of $637M as of April 04, 2025.
What is the P/E ratio for Gyre Therapeutics stock?
The price to earnings (P/E) ratio for Gyre Therapeutics (GYRE) stock is 141.44 as of April 04, 2025.
Does Gyre Therapeutics stock pay dividends?
No, Gyre Therapeutics (GYRE) stock does not pay dividends to its shareholders as of April 04, 2025.
When is the next Gyre Therapeutics dividend payment date?
Gyre Therapeutics (GYRE) stock does not pay dividends to its shareholders.
What is the beta indicator for Gyre Therapeutics?
Gyre Therapeutics (GYRE) does not currently have a Beta indicator.